Advertisement

Chemotherapy pp 183-186 | Cite as

ICRF 159 and Other Bisdioxopiperazines

  • K. Hellmann

Abstract

ICRF 159 ( (±)1,2-bis(.3, 5-dioxopiperazin-l-yl)propane) and a number of other bisdioxopiperazines are potent aptimetastatic compounds which inhibit the development of metastases from primary implants of the syngeneic Lewis lung carcinoma (3LL) in C57 BL mice (Hellmann & Burrage 1969; Salsbury, Burrage and Hellmann 1970). This effect is produced without evident influence on the growth rate of the primary tumour and thereby shows that it is possible to delete selectively one malignant characteristic of a tumour without influencing another. While this antimetastatic effect is not apparently unique amongst anticancer agents it seems to be the exception.

Keywords

Poor Selectivity Antimetastatic Effect Primary Implant Progression Free Interval Poor Blood Supply 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Hellmann, K. & Burrage, Karen. Nature 224 273–275 (1969).PubMedCrossRefGoogle Scholar
  2. 2.
    Salsbury, A.J., Burrage, Karen and Hellmann, K. (1970) British Medical Journal, 4, 344–346.PubMedCrossRefGoogle Scholar
  3. 3.
    Creighton, A.N., Hellmann, K. & Whitecross, Susan (1969) Nature, 222, 384–385.PubMedCrossRefGoogle Scholar
  4. 4.
    Salsbury, A.J., Burrage, Karen, & Hellmann, K. (1974). Cancer Research, 34, 843–849.PubMedGoogle Scholar
  5. 5.
    James, Sandra E. & Salsbury, A.J. (1974) Cancer Research, 34, 839–842.PubMedGoogle Scholar
  6. 6.
    Creighton, A.M. & Birnie, G.D. (1970) International Journal of Cancer, 5, 47–54.CrossRefGoogle Scholar
  7. 7.
    Hellmann, K. & Field, E.O. (1970) J. Nat. Cancer Inst. 44, 539–543.PubMedGoogle Scholar
  8. 8.
    Sharpe, Heather B.A., Field, E.O. & Hellmann, K. (1970) Nature, 226, 524–526.PubMedCrossRefGoogle Scholar
  9. 9.
    Hallowes, R.C., West, D.G. & Hellmann, K. (1974) Nature, 247 487–490.PubMedCrossRefGoogle Scholar
  10. 10.
    Goldin, A., Venditti, J. & Mantel, N. (1975). in Antineoplastic and immunosuppressive agents Vol 1. Eds. A.C. Sartorelli & D.G. Johns, Springer, New York.Google Scholar
  11. 11.
    Wampler, G.L. (1973). Minutes of ICRF 159 meeting, National Cancer Institute, Bethesda, U.S.A. Ed. Wasserman, T.H.Google Scholar
  12. 12.
    Woodman, R.J., Kline, I. & Venditti, J.M. (1972). Proc. Amer. Ass. Cancer Res. 13, 31.Google Scholar

Copyright information

© Plenum Press, New York 1976

Authors and Affiliations

  • K. Hellmann
    • 1
  1. 1.Cancer Chemotherapy DepartmentImperial Cancer Research FundLondonUK

Personalised recommendations